Slicing the salami
It’s time to look at progress on the ADC front, something we sporadically cover where there are new phase 1 or 2 data of note.
Making waves in the ADC niche
Compared to the myriad of targeted small molecules and IO therapies out there, ADCs and related drug conjugates form a much smaller class of agents, although this is slowly changing as the technology develops on several fronts.
Yesterday’s first plenary session at the 2021 Targets/Triple meeting focused on new developments in tumour-targeted conjugates including a couple of early stage projects, which should be well worth watching out for and following over time.
It wasn’t all plain sailing, however, with plenty of important caveats and nuances to be aware of…
BSB subscribers can read up on our latest commentary and analysis from the cancer conference season on our TRIPLE meeting coverage – you can log-in or click to access our latest analysis.
This content is restricted to subscribers
